Author of

• 25520

  +

  Poster Display session (Friday) (ID 65)

  • Event: ELCC 2018
  • Type: Poster Display session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1

  • 25417

    +

    221P - Treatment experience of pleural malignant mesothelioma in a tertiary referral center in Mexico (ID 533)

    12:30 - 13:00  |  Author(s): G. Nuñez-Cerrillo
    • Abstract

    Background:
    Malignant pleural mesothelioma (MPM) is considered a relatively rare tumor and has an extremely poor prognosis. There is a lack of data in Mexico where asbestos industry still exists. Therefore, the creation of databases is necessary to determine the dimension of this problem in our country.
    
    Methods:
    A retrospective study was performed including patients with MPM diagnosis attended between 2012 to 2016 at Hospital de Oncología, Centro Médico Nacional Siglo XXI in Mexico City. The objective of our study was to describe clinical characteristics and oncologic outcomes. A survival analysis was conducted taking into account the different treatment arms and clinical stages.
    
    Results:
    A total of 99 patients diagnosed with MPM and complete clinical records were included. 67% were men and 33% women. Median age at diagnosis was 64 years, 40.4% had a history of asbestos exposure, 66% had performance status 0–1. Pleural effusion was present in 97%. Most of the patients had advanced disease (65% stage IV and 29% stage III). 14.1% underwent pleurodesis. In 3% radical pleurectomy was performed. 15% received only palliative care with median overall survival of 3 months. First line regimens were pemetrexed with platin compound in 36.5%, while no pemetrexed-contained regimens were administered in 63.5% (gemcitabine/platinum in 49%). Overall response was 15.5% and stable disease 50%. Median overall survival and progression-free survival were 10 (0–50) months and 4 (0–8) months respectively, with no difference between treatment groups (p = 0.38). 29% received second-line therapy, most frequently (48%) oral vinorelbine-based regimens with clinical benefit of 46% and median PFS 3 (0–16) months.
    
    Conclusions:
    To our best knowledge, this is the largest report about the treatment of advanced MPM in Mexico. Limited by its retrospective design, this study confirms better outcomes in patients treated with chemotherapy and also highlights oral vinorelbine activity in second-line setting. Prognosis of advanced MPM is poor and prospective trials in Mexico are needed.
    
    Clinical trial identification:
    
    
    Legal entity responsible for the study:
    Hospital de Oncología, Centro Médico Nacional Siglo XXI, Departamento de Oncología Médica
    
    Funding:
    Has not received any funding
    
    Disclosure:
    All authors have declared no conflicts of interest.